U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. 7 Daze, LLC - 07/31/2018
  1. Warning Letters


7 Daze, LLC


7 Daze, LLC

United States

Issuing Office:

United States


Department of Health and Human Services logo

Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993 


JULY 31, 2018
VIA UPS and Electronic Mail
John Lau
7 Daze, LLC
13170 Spring Street
Baldwin Park, CA  91706
RE: Warning Letter issued to 7 Daze, LLC (RW1800845)
Dear John Lau:
On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Pink Sticks e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Pink Sticks e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children.
On July 11, 2018, July 17, 2018, and July 23, 2018, you sent FDA a response to the Warning Letter, and we held teleconferences on July 19, 2018 and July 25, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violation identified in the Warning Letter. We note that you may have other tobacco products with labeling and/or advertising that causes the product to be misbranded for similar reasons to those discussed above. You are responsible for taking any necessary actions to bring your tobacco products into compliance with the requirements of the law.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
VIA UPS and Electronic Mail
John Lau
7 Daze LLC
7629 Garvalia Avenue
Rosemead, CA 91770-3064
WhoIsGuard Inc.
NameCheap Inc.
Shopify Inc.
Back to Top